Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Xeris Pharmaceuticals ( (XERS) ) has issued an update.
On April 20, 2026, Xeris Biopharma Holdings, Inc. announced that Dr. Jeffrey Sherman, a director since 2021 and member of both the Compensation Committee and the Nominating and Corporate Governance Committee, notified the company of his decision to retire from the Board and not stand for reelection at the 2026 Annual Meeting of Stockholders. He will continue to serve until his term expires at that meeting, after which the Board will be reduced from eight to seven directors, with the company emphasizing that his decision was not due to any disagreement with management and publicly acknowledging his service, a move that signals an orderly governance transition with limited operational disruption.
The adjustment in Board size following Dr. Sherman’s retirement suggests a modest streamlining of governance rather than a strategic overhaul, indicating continuity in oversight structures for stakeholders. By clarifying that there are no underlying disputes and by formally recognizing his contributions, Xeris aims to reassure investors and other stakeholders that Board succession is being managed routinely and without controversy.
The most recent analyst rating on (XERS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.
Spark’s Take on XERS Stock
According to Spark, TipRanks’ AI Analyst, XERS is a Neutral.
The score is driven mainly by improved financial performance in 2025 (profitability inflection and positive free cash flow) and a constructive earnings outlook with strong 2026 growth guidance. These positives are tempered by weak technicals (downtrend/negative momentum), balance-sheet leverage risk, and limited valuation support given the negative P/E and no dividend yield.
To see Spark’s full report on XERS stock, click here.
More about Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on developing and commercializing therapies, with oversight provided by a Board of Directors and key committees such as the Compensation Committee and the Nominating and Corporate Governance Committee. Its governance structure reflects standard industry practices aimed at supporting strategic and operational decision-making in the life sciences sector.
Average Trading Volume: 1,797,395
Technical Sentiment Signal: Buy
Current Market Cap: $1.07B
See more data about XERS stock on TipRanks’ Stock Analysis page.